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Introduction {#sec1}
============

Jarid2 (Jumonji, AT-rich interactive domain 2) is the founding member of the Jumonji family of proteins that can demethylate histones, although Jarid2 itself is unable to do so ([@bib29; @bib31]). Jarid2 was discovered in 1995 as a regulator of neural development in a gene trap screen in mice ([@bib61]), and Jarid2 deficiency was later shown to result in a range of phenotypes with variable severity and onset with defects in heart and neural tube formation and hypoplasia of liver, spleen, and blood tissues ([@bib24; @bib31; @bib62]). In humans, mutations in Jarid2 have been linked to congenital defects including nonsyndromic cleft lip, spina bifida, and congenital heart abnormalities ([@bib55; @bib68]), and haploinsufficiency is linked to intellectual disability and brain dysfunction including schizophrenia ([@bib4; @bib9; @bib49; @bib51]). At the cellular level, Jarid2 is known to inhibit myogenic differentiation in mouse and human cells ([@bib70]), is important for the scheduled proliferation of epidermal stem and progenitor cells ([@bib42]), and is thought to input into cell-cycle control by regulating cyclin D1 ([@bib45; @bib67]). In embryonic stem cells (ESCs), Jarid2 is particularly abundant and has been implicated as a hub component of transcriptional networks that underpin pluripotency ([@bib1; @bib27; @bib38; @bib60; @bib77]). ESCs lacking Jarid2 remain viable and pluripotent but are unable to efficiently differentiate in culture and show alterations in growth kinetics and in colony morphology ([@bib32; @bib37; @bib48; @bib57]).

Jarid2 is a critical component of the Polycomb Repressor complex 2 (PRC2), implicated in guiding the deposition of H3K27me3 across the genome ([@bib32; @bib37; @bib48; @bib50; @bib57]). In ESCs, Jarid2 binds to a similar set of genomic sites as core PRC2 components, such as Embryonic ectoderm development (Eed), Suppressor of Zeste 12 (Suz12), and Enhancer of Zeste 2 (Ezh2) ([@bib32; @bib37; @bib48; @bib50; @bib57]). In *Drosophila*, Jarid2 also binds to sites that broadly overlap with other core PRC2 members, albeit at slightly different levels and with some exceptions ([@bib20]). Although these results support a role for Jarid2 in PRC2 recruitment, in concert with co-factors such as Aebp2, Pcl1, 2, 3, and esPRC2p48 ([@bib23; @bib25; @bib28; @bib37; @bib52; @bib69; @bib76]), the consequence of Jarid2 loss for H3K27me3 levels is unclear, as both increased ([@bib50; @bib57]) and decreased H3K27methylation have been reported ([@bib32; @bib37; @bib48]). In addition, recent studies of X-inactivation have shown that, while Jarid2 is necessary for efficient PRC2 recruitment, Jarid2 binds to Xist RNA-associated chromatin domains independently of PRC2 ([@bib14]). Jarid2 also binds to other non-coding RNAs in ESCs ([@bib26]) and has been shown to bind nucleosomes directly ([@bib58]). These findings suggest that Jarid2 may have multiple functions in pluripotent ESCs and could act as an intermediate in the chromatin events that occur as pluripotent cells move toward differentiation ([@bib14]). Consistent with this view, *Jarid2*-null ESCs grow and self-renew robustly in culture but are severely compromised in their capacity to generate mesoderm, endoderm, or ectoderm lineages in vitro ([@bib32; @bib57]). In vivo, *Jarid2*-null mouse embryos develop normally until E10.5 or beyond ([@bib24; @bib62]), suggesting that *Jarid2*-null ESCs may be capable of differentiation but fail to do so in standard in vitro cultures.

Here, we examined the properties of *Jarid2*-null ESCs derived from different sources, as well as the factors that were consistently de-regulated in these cells. Our results show that *Jarid2*-null ESCs express constitutively high levels of Nanog proteins, indicative of a "naive pluripotent state," together with dramatically reduced planar cell polarity (PCP) and Wnt signaling components. In particular, expression of Prickle1, Fzd2, Wnt9a, E-cadherin, and β-catenin activity were all reduced in *Jarid2*-null ESCs, while Wnt antagonists such as Sfrp1 were upregulated. Remarkably, this inverse correlation between PCP/Wnt signaling and Nanog expression was replicated in wild-type ESCs depleted of *Prickle1*/*Fzd2*/*Wnt9a*, or engineered to overexpress Nanog. Co-culture of *Jarid2*-null ESCs with wild-type partners allowed the mutant cells to regain variable Nanog expression and β-catenin activity and restored their capability for differentiation. Surprisingly, we showed that disruption of PCP/Wnt signaling early in mouse embryogenesis, by introducing *Jarid2*-null ESCs (but not *Eed*-null ESCs), resulted in multiple ICM formation. This emphasizes the importance of the Jarid2-Nanog-PCP/Wnt core circuit for normal development and revealed a non-canonical (PRC2-independent) role for Jarid2 in coordinating this process.

Results {#sec2}
=======

Jarid2 Affects Nanog Expression in ESCs Maintained in Serum and Leukemia-Inhibitory Factor {#sec2.1}
------------------------------------------------------------------------------------------

Pluripotency factor expression by ESCs has been generally assumed to be unaffected by deletion of PRC2 ([@bib3; @bib6; @bib35; @bib47; @bib56]). Consistent with this, *Jarid2*-null ESCs ([@bib32]) expressed substantial levels of each of the core pluripotency factors Oct4, Sox2, and Nanog as indicated by western blotting analysis ([Figure 1](#fig1){ref-type="fig"}A, clones E4 and E8). Surprisingly, however, we detected an inverse correlation between *Jarid2* gene dose and Nanog expression \[JM8(wild-type) \< A08(^+/−^) \< E4(^−/−^) and E8(^−/−^), [Figure 1](#fig1){ref-type="fig"}A\]. At the single-cell level, immuno-labeling for Nanog followed by fluorescence microscopy ([Figure 1](#fig1){ref-type="fig"}B) or flow cytometry analysis ([Figure 1](#fig1){ref-type="fig"}C) revealed that the increased expression of Nanog by *Jarid2*-null ESCs was due to a reduced proportion of Nanog-low cells. Specifically, *Jarid2*-null ESCs appeared homogenously Nanog-high ([Figure 1](#fig1){ref-type="fig"}B, lower panel shows Nanog^green^ labeling of virtually all Oct4^blue^ cells), whereas Nanog-high and -low cells were easily discerned among parental wild-type JM8 ESCs (upper panel). This difference was confirmed by flow cytometry (compare green and gray traces, [Figure 1](#fig1){ref-type="fig"}C) where mutant E8 cells showed a reduced proportion of Nanog-low cells. To verify that altered Nanog expression was due to Jarid2 depletion rather than simply clonal variation between different ESC lines, we examined the properties Jarid2 mutant cells that had been independently generated by others ([@bib57]). These *Jarid2*-null(^−/−^) ESCs also expressed constitutively high levels of Nanog protein detected by western blotting ([Figure 1](#fig1){ref-type="fig"}D), fluorescence-activated cell sorting (FACS) analysis ([Figure 1](#fig1){ref-type="fig"}E, 82% Nanog-high), and immunofluorescence microscopy ([Figure 1](#fig1){ref-type="fig"}F) (lower-right panel), as compared to matched wild-type controls (*Jarid2* fl/fl). In addition, we noticed that, among cells plated at low density, *Jarid2*-null ESCs failed to properly self-organize into coherent colonies appearing as either "spread" (such as E8) or "disorganized" overlapping layers of Nanog-high cells (white arrows). To quantify such defects, we assessed the nuclear shape and dimensions of four to eight cell colonies that arose after plating E8 and JM8 ESCs at limiting dilution ([Figure S1](#mmc1){ref-type="supplementary-material"}A). This unbiased comparison confirmed a profound difference in the nuclear height/width ratios of cells occupying central and peripheral positions within *Jarid2*-null colonies ([Figures S1](#mmc1){ref-type="supplementary-material"}B and S1C). Taken together, these data suggest that Jarid2 has a role in regulating both Nanog levels and cell-cell interactions in ESCs.

Prior studies of ESCs lacking PRC1 (Ring1B) or PRC2 (Eed) components have shown similar levels of Nanog and Oct4 as matched controls ([@bib15; @bib36]) suggesting that the effect of Jarid2 depletion on Nanog expression might not be mediated by PRC2. Furthermore, as Jarid2 does not directly bind to the Nanog promoter in mouse ESCs ([@bib48]), we investigated whether other repressors might be responsible for regulating Nanog expression differentially between *Jarid2*-null and wild-type ESCs. Chromatin immunoprecipitation (ChIP) analysis revealed that, although both cell lines expressed similar levels of Tcf3 ([Figure S1](#mmc1){ref-type="supplementary-material"}D), wild-type ESCs showed a significant enrichment for Tcf3 bound to a consensus site in the *Nanog* promoter, as compared to *Jarid2*-null samples ([Figure S1](#mmc1){ref-type="supplementary-material"}E). This result was consistent with Tcf3 mediating the repression of Nanog in ESCs ([@bib11]) and suggests that Jarid2 may modulate Tcf3 activity.

Jarid2 Regulates Non-canonical Wnt Signaling in Undifferentiated ESCs {#sec2.2}
---------------------------------------------------------------------

Tcf3 is a critical component of canonical Wnt signaling pathways that is implicated in regulating the balance between stem cell self-renewal and differentiation. Mouse ESCs maintained in media supplemented with inhibitors of glycogen synthase kinase 3 and Fgf-MAPK (2i) have elevated Nanog levels ([@bib71; @bib75]) and, like *Jarid2*-null ESCs, are less prone to differentiation. To discover genes downstream of Jarid2, we examined publically available gene-expression microarray data for *Jarid2*^−/−^ ESCs ([@bib57]) and found that among the 413 genes misregulated relative to controls (fold change \> 2, p value \< 0.05) many have roles in cell adhesion, the cytoskeleton, and extracellular matrix or are implicated in development ([Figure S2](#mmc1){ref-type="supplementary-material"}A). We examined published ChIP sequencing (ChIP-seq) data for Jarid2 binding in undifferentiated ESCs ([@bib48]) to uncover which genes might be directly regulated by Jarid2. Among the 1,146 genic promoters enriched for Jarid2 binding, we noticed a strong preference for genes critical in Wnt signaling (29 genes) and Wnt-related pathways ([Figure S2](#mmc1){ref-type="supplementary-material"}B). To explore this further, gene-expression profiling was performed to formally determine whether genes involved in Wnt signaling pathways were substantially deregulated in ESCs lacking Jarid2. For this, ESC clones that lacked Jarid2 (E8 and *Jarid2*^−/−^ cells) were compared with wild-type ESCs (JM8 and *Jarid2* fl/fl), and mRNA expression of Wnt signaling components was quantified by qPCR using commercially available PCR plates. Among the candidates showing significant de-regulation in ESCs lacking Jarid2 (p \< 0.05) were *Prickle1*, *Fzd2*, *Wisp1*, *Wnt9a*, and *Fosl1* (downregulated, [Figure 2](#fig2){ref-type="fig"}A, left) and *Aes*, *Dkk1*, *Sfrp1*, and *Wnt11* (upregulated, [Figure 2](#fig2){ref-type="fig"}A, right). These candidates included genes with binding sites for Jarid2 within their promoters (*Prickle*, *Fzd2*, *Fosl1*, *Wnt9a*, *Wnt11*, *Dkk1*, and *Sfrp1*, [Figure S2](#mmc1){ref-type="supplementary-material"}C) as reported previously ([@bib50]). Careful pairwise comparison of gene-expression levels relative to matched parental controls verified a significant up- or downregulation of these genes in *Jarid2*-null ESCs ([Figure 2](#fig2){ref-type="fig"}B, where black bars show wild-type and white bars indicate *Jarid2* nulls). Differences between the two sources of *Jarid2*-deficient ESCs were apparent only for *Dkk1*, where expression appears particularly sensitive to cell density (data not shown). Fzd2 and Prickle1 are both well-established core components of the non-canonical Wnt, or PCP pathway in mammals, Wnt11 is a ligand associated with PCP ([@bib18]), and Dkk1 and Sfrp1 are secreted Wnt inhibitors involved in PCP signaling in vertebrates ([@bib8; @bib53]) (as depicted schematically in [Figure 2](#fig2){ref-type="fig"}C).

To check whether *Jarid2*-null ESCs have defects in planar cell polarity, we examined the distribution of Prickle1 and Vangl1 proteins (green) in wild-type and *Jarid2*-null ESCs using immunofluorescence with previously characterized antisera ([Figure 2](#fig2){ref-type="fig"}D). Both proteins were abundant within the cytoplasm and nucleus of wild-type ESCs (upper panels), whereas in *Jarid2* nulls (E8^−/−^) Prickle1 and Vangl1 levels were reduced in nuclei and there was a paucity of both proteins in the cytoplasm. This difference was confirmed using quantitative analysis of labeling intensity ([Figure S2](#mmc1){ref-type="supplementary-material"}D) that showed a significant decrease (5- to 10-fold) in Prickle1 and Vangl1 in the cytoplasm of *Jarid2*-null ESCs. E-cadherin labeling was also low in *Jarid2*-null ESCs and appeared patchy ([Figure 2](#fig2){ref-type="fig"}D, green lower right) as compared with contiguous labeling of cell boundaries in colonies of wild-type ESCs ([Figure 2](#fig2){ref-type="fig"}D, green upper right). These data highlight a deficiency of PCP proteins in *Jarid2*-null ESCs.

To extend this analysis, we generated three additional *Jarid2*-null ESC lines, using CRISPR/Cas9 to engineer mutations into the third exon of *Jarid2* ([Figures S2](#mmc1){ref-type="supplementary-material"}E--S2G). Clones were selected that showed frameshift mutation to both endogenous Jarid2 alleles ([Figure S2](#mmc1){ref-type="supplementary-material"}G), and western blots confirmed the absence of detectable Jarid2 proteins ([Figure 2](#fig2){ref-type="fig"}E). RT-PCR analysis showed that *Prickle1*, *Fzd2*, and *Wnt9a* expression was significantly reduced in each mutant clone relative to parental ESCs ([Figure 2](#fig2){ref-type="fig"}F), and flow cytometry analysis ([Figure 2](#fig2){ref-type="fig"}G) indicated a characteristic switch to constitutive Nanog-high expression (green versus gray trace) as illustrated for a Jarid2^CRISPR^\#3 mutant cells. This extends previous observations made with established *Jarid2*-null lines, indicating that deregulated PCP and Nanog expression was likely to be a direct consequence of Jarid2 removal rather secondary effects or adaption to culture.

Using a similar CRISPR/Cas9 approach, we also generated ESC lines lacking Prickle1, Fzd2, and Wnt9a ([Figures S2](#mmc1){ref-type="supplementary-material"}E--S2G). Six clones were identified with frameshift mutations in one or both alleles of each of these genes, and each mutant cell line showed a switch to constitutive Nanog-high expression and defects in colony formation ("spread" or "layered" cells) that resembled *Jarid2*-null ESCs. This is exemplified for PCP^CRISPR^\#5 ([Figures 2](#fig2){ref-type="fig"}H--2J), a clone with frameshift mutations in both endogenous *Prickle1* and *Fzd2* alleles and a single *Wnt9a* allele ([Figure S2](#mmc1){ref-type="supplementary-material"}G). This cell line showed dramatically reduced expression of all three genes ([Figure 2](#fig2){ref-type="fig"}H), expressed Nanog constitutively ([Figure 2](#fig2){ref-type="fig"}I, green) ([Figure 2](#fig2){ref-type="fig"}J, green trace), and showed aberrant clonal morphology ([Figure 2](#fig2){ref-type="fig"}I, right, arrows). Taken together, these data showed a hitherto-unrecognized role for Jarid2 in regulating non-canonical Wnt signaling and Nanog expression in undifferentiated ESCs.

Although Jarid2 binds to the promoters of *Prickle1*, *Fzd2*, *Wnt9a*, *Wnt11*, *Dkk1*, and *Sfrp1* ([@bib48]) ([Figure S2](#mmc1){ref-type="supplementary-material"}C), ChIP analysis revealed similar H3K27me3 levels at these targets in *Jarid2*-wild-type (JM8), heterozygous (A08), and null ESC lines (E4, E8) ([Figure S3](#mmc1){ref-type="supplementary-material"}A). This observation, together with the fact that Prickle1, Fzd2, and Wnt9a expression apparently requires Jarid2, suggests that Jarid2 may regulate PCP/Wnt signaling in ESCs in a way that is independent of its canonical role as a component of PRC2. A comparison of the replication timing of a panel of genes involved in PCP/Wnt signaling in wild-type (black bars) and *Jarid2*-null ESCs (white bars, [Figure S3](#mmc1){ref-type="supplementary-material"}B) also showed similar temporal profiles, suggesting that the chromatin structure of these genes was not radically different in the absence of Jarid2.

β-Catenin Activity Is Reduced in ESCs that Lack Jarid2 or Overexpress Nanog {#sec2.3}
---------------------------------------------------------------------------

We examined whether canonical Wnt signaling (β-catenin mediated) was also impaired in ESCs lacking Jarid2. As shown in [Figure 3](#fig3){ref-type="fig"}A, western blots revealed broadly similar amounts of β-catenin in whole-cell extracts derived from *Jarid2*-null (E8), heterozygous (A08), and wild-type ESCs (JM8). However, using antibody specific for active forms of β-catenin ([Figure 3](#fig3){ref-type="fig"}B), we observed reduced levels of active β-catenin in ESCs lacking Jarid2 (E8, *Jarid2*^−/−^) compared to wild-type cells (JM8, *Jarid2*fl/fl). This reduction was confirmed in functional assays using TOPFlash (luciferase-based) reporters. β-catenin activity was significantly reduced in both established (E8 and *Jarid2*^−/−^) and newly generated (Jarid2^CRISPR^\#3) *Jarid2*-null ESCs ([Figure 3](#fig3){ref-type="fig"}C, white bars) compared with controls (black bars), and also in Prickle1/Fzd2/Wnt9a depleted ESCs (PCP^CRISPR^\#5, gray bar). Since each of these mutant ESCs also expressed Nanog constitutively, we asked whether Nanog expression per se was important for reduced β-catenin activity. ESCs that stably express elevated levels of Nanog ([Figure 3](#fig3){ref-type="fig"}D, Nanog^OE^ white bars) were generated as described previously ([@bib66]). These cells showed significant reductions in β-catenin activity and reduced expression of Fzd2, Prickle1, and Wnt9a ([Figures 3](#fig3){ref-type="fig"}E and 3F), providing compelling evidence of a robust regulatory circuit between Nanog, PCP and β-catenin activity that is sensitive to Jarid2 (illustrated in [Figure 3](#fig3){ref-type="fig"}G). Operationally, this balance between Nanog and Wnt signaling was also evident in ESCs expressing wild-type levels of Nanog ([@bib10]), where Nanog expression and β-catenin activity were inversely correlated ([Figure 3](#fig3){ref-type="fig"}H).

*Jarid2*-Null ESCs Have Defects in Cell Sorting and Differentiation that Can Be Partially Rescued by Co-culture with Jarid2 Wild-Type ESCs {#sec2.4}
------------------------------------------------------------------------------------------------------------------------------------------

ESCs lacking Jarid2 grow as "spread" or "layered" colonies that respond poorly to differentiation cues ([@bib32]). To better understand whether defective Wnt signaling in *Jarid2*-null ESCs might underlie their inability to form coherent differentiation-responsive colonies, we initiated a series of cell mixing/sorting experiments in which *Jarid2*-null E8 cells were co-cultured with wild-type or *Jarid2* heterozygous partners. E8 cells express GFP ([@bib32]) allowing these cells to be easily tracked in co-culture. ESCs were mixed in a 1:1 ratio, plated on gelatin-coated plates, and analyzed 16--24 hr after mixing ([Figure 4](#fig4){ref-type="fig"}A). *Jarid2*-null ESCs were unable to form tight colonies when plated alone or with heterozygous (A08) partners (top, green), but this capacity was restored when mixed with (unlabeled) wild-type ESCs ([Figure 4](#fig4){ref-type="fig"}A, lower image). Co-culture of E8 cells with wild-type ESCs also resulted in preferential sorting of mutant cells to the periphery of colonies ([Figure 4](#fig4){ref-type="fig"}A, histograms right), similar to the peripheral sorting of Nanog-high cells seen in wild-type JM8 colonies ([Figure 1](#fig1){ref-type="fig"}F). Although co-culture of E8 and wild-type ESCs increased overall E-cadherin expression in mixed colonies ([Figure S4](#mmc1){ref-type="supplementary-material"}A, red), a close examination revealed that E-cadherin expression by mutant cells remained low in cultures at 16 hr ([Figure S4](#mmc1){ref-type="supplementary-material"}B). These data showed that *Jarid2*-null ESCs have intrinsic defects in canonical and non-canonical Wnt signaling, likely to contribute to aberrant cell-cell interactions.

Remarkably, co-culture of *Jarid2*-null (GFP^+^) ESCs with wild-type partners resulted in a switch from constitutive Nanog-high expression ([Figure 4](#fig4){ref-type="fig"}B, E8^−/−^ left) to a profile that was indistinguishable from wild-type ESCs ([Figure 4](#fig4){ref-type="fig"}B, E8^−/−^ right). Exposure of *Jarid2*-null ESCs to wild-type ESCs also restored β-catenin activity in the mutant cells ([Figure 4](#fig4){ref-type="fig"}C) and improved their capacity to differentiate ([Figures 4](#fig4){ref-type="fig"}D and 4E). Following co-culture and leukemia-inhibitory factor (LIF) withdrawal, *Jarid2*-null E8-derived (GFP) cells expressing neural-associated markers such as Nestin and Mash1 (red) were readily identified within mixed cultures (47% of GFP^+^ cells expressed Nestin). Neural induction was less efficient than in control wild-type cultures (\>80% Nestin positive by day 10, [Figure S4](#mmc1){ref-type="supplementary-material"}C), and fewer cells were recovered overall (5%--10%). Co-culture of E8 cells with *Jarid2*-null ESCs, fibroblasts, T or B cells, or with conditioned media derived from wild-type ESCs did not rescue the capability of E8 cells to differentiate (data not shown) or enhance β-catenin activity in these cells (as shown in [Figure S4](#mmc1){ref-type="supplementary-material"}D). Because β-catenin activity is reportedly required for ESC differentiation ([@bib2; @bib39]), *Jarid2*-null ESCs may be unable to execute differentiation efficiently because of low β-catenin activity. In this scenario, co-culture with wild-type ESCs restores β-catenin activity and may enable mutant ESCs to differentiate ([Figure S4](#mmc1){ref-type="supplementary-material"}E shows a hypothetical scheme).

Cytoplasmic Prickle1 Distribution Marks the Developing Epiblast In Vivo {#sec2.5}
-----------------------------------------------------------------------

To investigate whether Jarid2 regulation of Nanog PCP/Wnt signaling is likely to be important in vivo as well as in vitro, we examined the distribution of Prickle1 in the pre-implantation mouse embryo. Depletion of PCP components, including Prickle1, has been reported to lead to defects in cell adhesion that affect the development of early mouse embryos ([@bib34; @bib44; @bib63]), and previous studies have shown that although Prickle1 is detected at E5.5 and earlier ([@bib63; @bib64]), canonical Wnt signaling is operational slightly later in development ([@bib44]). We examined mouse embryos from E3 to E4.5 for Prickle1 expression using DAPI as a counterstain (blue) to assess cell number. Immuno-labeling with antibodies to Nanog (red), Oct4 (data not shown), or Gata6 (red) was used to assess the stage and orientation of the developing inner cell mass (ICM) ([Figures 5](#fig5){ref-type="fig"}A and 5B). As illustrated in [Figure 5](#fig5){ref-type="fig"}A, Prickle1 (green) was abundantly detected in 32- and 64-cell embryos and showed a prominent cytoplasmic distribution in Nanog positive cells destined to form the epiblast (region outlined in white, [Figure 5](#fig5){ref-type="fig"}A). By E4.5, Nanog-high cells were condensed to the pole of the embryo where they expressed high levels of Prickle1 distributed equivalently between nuclei and cytoplasm. The surrounding Gata6-expressing cells (red) also expressed high levels of Prickle1 (green), but in this case expression was predominantly nuclear ([Figure 5](#fig5){ref-type="fig"}B, region highlighted in white). Most cells in the polar trophectoderm showed modest levels of mostly nuclear Prickle1. An exception was of a small group of two to six mural trophectoderm cells, in which Prickle1 expression was high and located in nuclei and particularly within nucleoli (summarized in the schematic diagram shown in [Figure 5](#fig5){ref-type="fig"}C). The selective distribution of cytoplasmic Prickle1 in cells of the epiblast versus primitive endoderm or trophectoderm was confirmed in optical sections of E4.5 embryos as shown in [Figure S5](#mmc1){ref-type="supplementary-material"}A (green labeling and traces). E-cadherin (red, [Figure 5](#fig5){ref-type="fig"}D) was prominent throughout the blastocyst at these stages.

*Jarid2*-Null ESCs Initiate Multiple ICMs upon Injection into Normal Blastocysts {#sec2.6}
--------------------------------------------------------------------------------

ESCs that lack Jarid2 expressed high levels of Nanog and low levels of Prickle1, Vangl1, and β-catenin activity and show severely compromised differentiation ([@bib32]). As these defects were partially compensated by in vitro co-culture with wild-type ESCs, we asked to what extent mutant cells would contribute to the developing embryo. Wild-type E3.5 blastocysts were injected with either 10--15 GFP^+^*Jarid2*-null ESCs (E8) or an identical number of GFP-labeled wild-type ESCs (JM8) and then were cultured for 16--20 hr before being examined. Remarkably, we found that blastocysts injected with *Jarid2*-null ESCs routinely initiated the formation of more than a single ICM (16/39, illustrated in [Figure 5](#fig5){ref-type="fig"}E, lower panels), a feature that was not detected in any of the controls injected with wild-type ESCs (0/90, upper panels). Importantly, although these secondary ICMs appeared to be focused around small clusters of *Jarid2*-null ESCs (marked in green), in which higher levels of Nanog might be anticipated, Gata6 expression (red) was induced in the underlying wild-type cells ([Figure 5](#fig5){ref-type="fig"}F). This suggested that injection the mutant ESCs was sufficient to instruct neighboring wild-type blastomeres to upregulate Gata6 and thus contribute to the formation of multiple ICMs. To distinguish whether multiple ICM formation was due to defective PRC2 function, or defective Nanog, PCP, and Wnt circuitry, we injected E3.5 blastocysts with ESCs lacking Prickle1/Fzd2/Wnt9a, overexpressing Nanog, or that lacked *Eed* ([@bib3]) a core component of the PRC2 complex. As shown in [Table 1](#tbl1){ref-type="table"}, injection of wild-type (E14) and *Eed*-deficient (B1.3) ESCs generated only a single ICM in multiple experiments, whereas blastocysts injected with equivalent numbers of *Jarid2*-null (Jarid2^CRISPR^\#3), Prickle1/Fzd2/Wnt9a-depleted (PCP^CRISPR^\#5), or Nanog^OE^-overexpressing ESCs formed multiple ICMs in approximately 35%--48% of samples.

Discussion {#sec3}
==========

Our studies reveal several important and unanticipated results. First, we show that Jarid2, a Polycomb group member implicated in PRC2 recruitment, chromatin structure, and gene repression, acts as a positive regulator of PCP/Wnt signaling pathways in ESCs. Absence of Jarid2 or depletion of Prickle1/Fzd2/Wnt9a results in constitutive Nanog expression by ESC, which, in turn, results in reduced levels of active β-catenin. These observations identify an important Jarid2-sensitive core circuit in ESCs that regulates pluripotency and differentiation. In previous studies, *Jarid2*-null ESCs were shown to have a profoundly compromised ability to differentiate in culture ([@bib32; @bib37; @bib48; @bib50; @bib57]). Here, we show that canonical and non-canonical Wnt signaling is reduced in *Jarid2*-null ESCs, and these cells are unable to establish coherent colonies with each other. Introduction of wild-type ESCs supports the formation of colonies and increases β-catenin activity within *Jarid2*-null ESCs, allowing them to properly execute differentiation programs in response to appropriate cues, although the nature of the support offered by wild-type ESCs is at present unclear.

These results are perhaps surprising in view of reports implicating Jarid2 in the regulation of Notch1 ([@bib43]), or showing that Nanog represses the expression of Dkk1 (a secreted Wnt inhibitor) in ESCs to enhance β-catenin expression ([@bib41]). Current literature contains many conflicting reports on whether β-catenin is essential or dispensable for maintaining ESC pluripotency ([@bib46; @bib59; @bib65; @bib72; @bib75]). This discrepancy probably reflects the fact that β-catenin is pleotropic and regulates both gene transcription and cell adhesion (reviewed in [@bib7] and [@bib21]). In addition, the requirement for and effects of β-catenin appear to be context dependent ([@bib39; @bib46; @bib72; @bib74]) and are reported to differ between naive and primed ESCs ([@bib30; @bib65]). Our data show that *Jarid2*-null ESCs maintained in LIF and serum have low β-catenin activity despite unchanged levels of total protein. These cells can self-renew but have an impaired capacity to differentiate. Co-culture of mutant cells both restored β-catenin activity and allowed them to differentiate, consistent with several reports showing that nuclear β-catenin is required to execute differentiation in vitro ([@bib2; @bib39]) and in vivo ([@bib19; @bib22]).

Previous studies have shown that non-canonical Wnt signaling is present in mouse blastocyst before implantation ([@bib63; @bib64]). Early blastomeres express cytoplasmic Dishevelled (Dvl) proteins but may not activate canonical Wnt signaling as judged by sensitive BAT-gal Wnt reporters ([@bib44]). Overexpression of Dvl, a downstream target of Prickle1, Vangl, and Frizzled (Fz) ([@bib17; @bib33]), has been shown to dramatically alter the morphology and adhesion properties of 4-cell stage mouse embryos, resulting in a lack of coherence in the resulting blastocyst ([@bib44]). Likewise, deletion of Prickle1 in mouse embryos results in local disorganization of epiblast tissue ([@bib63]) and early embryonic death (E5.5--E6.6), while lower levels of Wnt9a promotes cell proliferation ([@bib73]). Here, we show that PCP expression is reduced in *Jarid2*-null ESCs, and their introduction into E3.5 blastocysts induces the formation of multiple ICMs in around half of the embryos. Canonical Wnt signaling is thought to begin at implantation in the mouse ([@bib44]), and it is tempting to speculate that the group of cells in the mural trophectoderm identified by high levels of Prickle1 in nucleoli may be cells destined to mediate implantation into the uterus. Whatever the explanation, our demonstration that wild-type cells can rescue the differentiation of *Jarid2*-null ESCs in vitro may provide important insights for understanding the conflicting differentiation status of Jarid2 cells in vivo and in vitro. In homogenous clonally derived cultures, mutant cells are unable to establish bona fide cell-cell interactions or enhance β-catenin activity, whereas in heterogenous cultures (with wild-type ESC partners) or in vivo (with other blastocyst-derived cells) β-catenin activity and PCP/Wnt signaling may be partially compensated.

Our discovery that Jarid2 is a regulator of PCP/Wnt is also important for re-evaluating some of the emerging evidence that *Jarid2* mutations (or SNPs) are risk factors for several human diseases. Genetic studies have for example linked Jarid2 with nonsyndromic cleft lip ([@bib55]). In mice, Jarid2 is highly expressed in epithelial cells and in the merging palatal shelves. In this context, as well as in congenital heart defects where Jarid2 mutations have also been reported ([@bib68]), the potential for *Jarid2* mutations to de-regulate PCP/Wnt signaling might be very informative for understanding the molecular basis of these malformations and could potentially offer different opportunities for intervention. In the case of cancer, *Jarid2* mutations have been linked to metastases at diagnosis in soft-tissue sarcoma ([@bib70]), to non-small cell lung carcinoma ([@bib40]), T-ALL, and to myeloproliferative disease ([@bib54]). Although it is possible that Jarid2 has an impact on these diseases based on its canonical role in PRC2-mediated chromatin modulation, it is also possible that Jarid2 is more directly involved in metastatic progression through its potential impact on cell sorting, cellular adhesion, and PCP/Wnt signaling. Thus, in addition to influencing PRC2 recruitment and H3K27 HMTase activity in ESCs, we have shown that Jarid2 is necessary to maintain a balance between Nanog expression and PCP/Wnt/β-catenin in ESCs that is essential to enable them to properly respond to differentiation cues. Regulation of this core circuit is also critical for normal pre-implantation development, since it appears to enable clusters of developing blastocysts to be discriminated and form a single inner cell mass. The discovery that Jarid2 regulates PCP/Wnt signaling in addition to its canonical role in PRC2 highlights an important intersection between cell signaling and chromatin-based regulation, relevant for understanding the interplay between pluripotency and differentiation.

Experimental Procedures {#sec4}
=======================

Detailed experimental procedures are available in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Mouse ESC Culture {#sec4.1}
-----------------

ESC lines were grown using standard conditions on 0.1% gelatin-coated dishes in the presence of LIF and 10% fetal calf serum. Neural differentiation was carried out as described previously ([@bib13]).

Wnt Signaling Pathway and Gene-Expression Analysis {#sec4.2}
--------------------------------------------------

Analysis of Wnt signaling pathway genes was performed using SYBR Green PCR array RT^2^ profiler (SABioscience). Gene-expression analysis by RT-qPCR using SYBR Green (QIAGEN) was performed as previously described ([@bib32]).

Western Blot, Immunofluorescence, and Flow Cytometry Analysis {#sec4.3}
-------------------------------------------------------------

Western blots were carried out using the following antibodies: mouse antisera to total β-catenin (BD Biosciences) and active β-catenin (Millipore), rabbit antisera to Nanog (Cosmo Bio), Jarid2 (Abcam), and goat antisera to Oct4 (Santa Cruz Biotechnology), Sox2 (Santa Cruz), Tcf3 (Santa Cruz), and Lamin B (Santa Cruz). Immunofluorescence analyses of ESC colonies and mouse blastocysts were carried out using the following primary antibodies: mouse antibodies against Oct4 (BD), E-cadherin (BD), Mash1 (BD); rabbit antisera against Nanog (Cosmo Bio), Vangl1 (Sigma), and Prickle1 (gift from A.G. Bassuk) ([@bib5]); and goat antisera against Gata6 (R&D Systems) and Nestin (Santa Cruz). Flow cytometry analysis of Nanog expression was carried out as previously described ([@bib16]) with the following modifications: 2 × 10E^5^ cells were stained using rabbit antisera against Nanog (2.5 μg/ml, Cosmo Bio) and anti-rabbit conjugated to Alexa 647 (6 μg/ml, Molecular Probes).

Injections of ESCs into Mouse Blastocysts {#sec4.4}
-----------------------------------------

10 to 15 GFP-expressing ESCs were injected in the inner cell mass of C57BL/6 blastocysts at E3.5. Injected embryos were cultured for 16 hr in KSOM media after which they were fixed for immunofluorescence analysis.

CRISPR/Cas9-Mediated Genome Editing {#sec4.5}
-----------------------------------

Single-guide RNA sequences were cloned into human codon optimized SpCas9 and chimeric guide RNA expressing px330 plasmid ([@bib12]) followed by co-transfection into ESCs. Individual ESC clones were picked and sequenced to identify mutations.

TOPFlash Assays {#sec4.6}
---------------

Cells (10^6^ per well) were transfected with 1 μg TOPFlash and 0.1 μg Renilla luciferase plasmids in 6-well plates using Lipofectamine 2000 reagent (Life Technologies) and analyzed using the Dual Luciferase Reporter Assay System (Promega).

Tcf3 and H3K27me3 ChIP Analyses {#sec4.7}
-------------------------------

2 × 10^7^ ESCs were crosslinked using 1% formaldehyde. Tcf3 ChIP was carried out as described previously ([@bib11]). H3K27me3 ChIP was carried out as described previously ([@bib32]).

Animal Procedures {#sec4.8}
-----------------

Animals used in the study were maintained and handled according to the guidelines of the Imperial College Animal Welfare Ethical Review Committee and the regulations set out by the British Home Office.

Author Contributions {#sec5}
====================

A.G.F and D.L. conceived the study. Crispr/Cas9 mutation and β-catenin activity were assessed by H.B. and A.R.M. respectively, I.C. evaluated replication timing, N.B., Z.W., K.E.B., and E.N. performed embryo staining and injection.
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![*Jarid2*-Null ESCs Express Constitutively High Levels of Nanog Protein\
(A) Western blot analysis of whole-cell extracts showing Nanog, Oct4, and Sox2 levels in wild-type (JM8^+/+^), Jarid2 heterozygous (A08^+/--^), and two Jarid2 knockout ESC lines (E4^--/--^ and E8^--/--^). Lamin B provides a loading control.\
(B) Confocal images of Nanog (green) and Oct4 (blue) immunofluorescent labeling of wild-type (JM8^+/+^) and *Jarid2*-null (E8^--/--^) ESC cultures. Scale bar, 100 μm.\
(C) FACS analysis of Nanog expression by JM8 (^+/+^, upper) and E8 (^--/--^, lower) ESCs. Histograms (right) show Nanog detection in JM8 (filled gray) and E8^--/--^ (green) cultures in which labeling using an isotype control is shown as a black line.\
(D) Western blot analysis of whole-cell extracts comparing Nanog and Oct4 protein levels in *Jarid2* fl/fl and *Jarid2*^--/--^ ESCs lines ([@bib57]). Lamin B provides a loading control.\
(E) Comparison of Nanog expression among *Jarid2* fl/fl and *Jarid2*^−/−^ ESCs evaluated by flow cytometry. FACS plots (left) and histograms (right) show Nanog detection in wild-type (*Jarid2* fl/fl, filled gray) and *Jarid2*-null ESC lines (*Jarid2*^--/--^, green).\
(F) Representative confocal images of colonies of wild-type (JM8^+/+^, *Jarid2* fl/fl) and *Jarid2*-null (E8^--/--^, *Jarid2*^--/--^) ESCs, plated at low density where Nanog labeling (green) and DAPI stain (blue) are shown. White arrows show characteristic layers or "stacks" of Nanog-high cells in *Jarid2*^--/--^ colonies. Scale bar, 10 μm.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr1){#fig1}

![Jarid2 Regulates a Subset of Planar Cell Polarity and Wnt Signaling Genes in ESCs\
(A) qPCR array comparison of gene-expression levels of Wnt signaling genes in pooled samples of Jarid2 wild-types (triplicates of JM8^+/+^ and *Jarid2* fl/fl) and Jarid2 mutants (triplicates of E8^−/−^ and *Jarid2*^--/--^). Gene-expression differences (x axis) are plotted against statistical significance (y axis), and each dot represents a single gene. Most significantly down- (left, green) or upregulated (right, red) genes are labeled.\
(B) RT-PCR analysis of Wnt signaling genes expressed by wild-type (JM8^+/+^ black bars) and *Jarid2*-null (E8^--/--^ white bars) ESCs are shown in the upper panel and by matched wild-type (*Jarid2* fl/fl black bars) and *Jarid2*-null (*Jarid2*^--/--^ white bars) in the lower panel. Actb and Rex1 were used as controls for these analyses, and the results shown are the mean ± SD of three experiments, where asterisks indicate statistical significance (p \< 0.05, Student's t test).\
(C) A simplified scheme of Wnt signaling pathways contributing to cytoskeletal and transcriptional changes in cells.\
(D) Confocal images showing labeling of Prickle1, Vangl1, and E-cadherin (green) and DAPI (blue) staining in wild-type (JM8^+/+^) and *Jarid2*-null (E8^--/--^). Scale bar, 10 μm.\
(E) Western blots of whole-cell extracts confirm that Jarid2 is absent from Jarid2^CRISPR^ ESC clones 1, 2, and 3, using parental E14 wild-type cells as controls. Lamin B provides a loading control; size markers are as indicated.\
(F) RT-PCR analysis of Prickle1, Fzd2, and Wnt9a transcript levels in wild-type E14 ESCs and Jarid2^CRISPR^ clones 1, 2, and 3. Actb and Rex1 were used as controls; results show mean ± SD of three experiments, and asterisks indicate statistical significance (p \< 0.05, Student's t test).\
(G) Comparison of Nanog expression by Jarid2^CRISPR^ targeted ESCs (clone 3, green) and parental wild-type E14 ESCs (filled gray) evaluated by flow cytometry. A black line shows labeling by isotype controls.\
(H) RT-PCR analysis of Prickle1, Fzd2, Wnt9a transcript levels in wild-type E14 ESCs (wt, black bars) and in PCP^CRISPR^ clone 5 (gray bars) where DNA sequencing analysis confirmed that both alleles of Prickle1 and Fzd2, and a single allele of Wnt9a contain frameshift mutations ([Figures S2](#mmc1){ref-type="supplementary-material"}G--S2I). Results were normalized to *Hmbs*, and the mean ± SD of three independent experiments is shown.\
(I) Representative confocal images show constitutive Nanog expression (green) and aberrant colony formation by PCP^CRISPR^\#5 ESCs (deficient in Prickle1, Fzd2, Wnt9a). Characteristic "layering" of Nanog positive mutant cells is highlighted (white arrow), and parental wild-type cells are shown for comparison (DAPI, blue). Scale bar, 10 μm.\
(J) Nanog expression by PCP^CRISPR^\#5 ESCs (green) and wild-type E14 ESCs (filled gray) was evaluated by flow cytometry, and isotype controls are indicated by a black line.\
See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Sustained β-Catenin Activity and PCP Expression in ESCs Requires Jarid2 and Is Sensitive to Nanog Overexpression\
(A) Western blot analysis of whole-cell extracts show similar levels of total β-catenin in wild-type (JM8^+/+^), Jarid2 heterozygous (A08^+/--^), and -null (E8^--/--^) ESCs. Lamin B provides a loading control.\
(B) Western blots of active β-catenin detected in *Jarid2*-null (E8^−/−^, *Jarid2*^−/−^) versus parental ESC lines. Nanog is shown for comparison; Lamin B provides a loading control.\
(C) β-catenin activity, evaluated by luciferase-based TOPFlash assays comparing matched pairs of wild-type (black bars) and *Jarid2*-null (white bars) ESCs: JM8:E8 (left), *Jarid2* fl/fl: *Jarid2*^−/−^ (middle), wt:*Jarid2*^CRISPR^\#3 (right). Reduced β-catenin activity was evident in ESCs lacking Prickle1/Fzd2/Wnt9a (PCP^CRISPR^\#5, gray bar). Mean ± SD of three experiments are shown; asterisks indicate statistical significance (p \< 0.05; Student's t test).\
(D) RT-PCR analysis confirm a 7-fold increase in Nanog expression in ESCs engineered to overexpress Nanog (Nanog^OE^, white bar), compared to wild-type (black bar).\
(E) TOPFlash assays show reduced β-catenin activity in Nanog^OE^ ESCs (white bar) as compared with wild-type ESCs (wt, black bar). Mean ± SD of three experiments, where asterisks show statistical significance (p \< 0.05; Student's t test).\
(F) RT-PCR analysis of Fzd2, Prickle1, and Wnt9a transcripts detected in wild-type (black bars) and Nanog^OE^ (white bars) ESCs. Mean ± SD of three experiments; asterisks show statistical significance (p \< 0.05; Student's t test).\
(G) Schematic representation of the interdependency of Nanog, PCP, and active β-catenin expression in ESCs, revealed through studies of Jarid2 depletion.\
(H) ESCs carrying a Nanog-GFP reporter (TNG) were used to sort cells expressing high (light gray), medium (gray), or low levels (dark gray) of Nanog ([@bib10]) as shown in the upper panel, and β-catenin activity was compared using TOPFlash (lower panel). Unsorted TNG ESCs (black) are shown for comparison. Results show mean ± SD of three independent experiments.](gr3){#fig3}

![Differentiation of *Jarid2*-Null ESCs Is Restored following Co-culture with Wild-Type ESCs\
(A) Cell mixing experiments were designed to analyze the cell-cell sorting properties of *Jarid2*-null ESCs (left). Confocal immunofluorescence images (middle) show GFP-marked *Jarid2*-null ESCs (E8^−/−^, green) 16 hr after being cultured alone or mixed in a 1:1 ratio with GFP-negative A08 (*Jarid2*^+/−^) or JM8 (*Jarid2*^+/+^). Histograms (right) show the proportion of colonies where *Jarid2*-null cells sort to the periphery of mixed colonies. Scale bar, 10 μm.\
(B) FACS analysis of Nanog expression by JM8 and E8 cells before mixing (left), and by E8^−/−^ cells (GFP sorted) 24 hr after co-culture with wild-type ESCs.\
(C) Histograms show β-catenin activity evaluated using TOPFlash in GFP-sorted E8 ESCs before and after co-culture with wild-type ESCs (1:3 ratio) for 24 and 72 hr (white bars). β-catenin activity in JM8 cells provides a control (black bar). Results show mean and SE of three replicates; asterisks show statistical significance (p \< 0.05; Student's t test).\
(D and E) Confocal images showing Nestin (D) or Mash1 (E) immuno-labeling (red) of GFP-labeled E8-derived cells (*Jarid2* null, green) at 10--12 days after co-culture with wild-type (JM8-unlabelled) ESCs and differentiation. DAPI stain (blue). Scale bar, 10 μm. Nestin positive cells accounted for 47% of the total GFP-labeled E8-derived cells at this time, whereas very few viable E8 cells were recovered in parallel "unmixed" cultures, and Nestin expression was not detected ([@bib32]). Scale bars, 20 μm (Nestin), 10 μm (Mash1).\
See also [Figure S4](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![ESCs Lacking Jarid2 Induce the Formation of Multiple ICMs upon Injection into E3.5 Mouse Blastocysts\
(A) Confocal immunofluorescence images show mouse blastocysts at 32-cell (left panel), 64-cell (middle panel), or E4.5 (right panel) stages of development, immuno-labeled for Nanog (red), Prickle1 (green), and DAPI stain (blue). The dotted white line highlights the inner cell mass (32- and 64-cell stage), or epiblast (E4.5), indicated by high Nanog levels. Scale bar, 10 μm.\
(B) Representative confocal images show Gata6 (red), Prickle1 (green) labeling, and DAPI staining (blue) of E4.5 blastocysts. The dotted white line marks the primitive endoderm as defined by high Gata6 expression.\
(C) Schematic summary of Nanog, Gata6, and Prickle1 distribution in E4.5 blastocysts.\
(D) Representative confocal image of a E4.5 blastocyst labeled for E-cadherin (red), Prickle1 (green), and DAPI (blue) stain. Scale bar, 10 μm.\
(E) Representative confocal images of wild-type blastocysts that were labeled for Nanog (red) at E4.5, that had been previously injected (E3.5) with ten to 15 GFP labeled wild-type (JM8) ESCs (upper panels) or GFP-labeled *Jarid2*-null (E8) ESCs (lower panels). A single ICM was detected all (90) samples injected with wild-type ESCs, whereas multiple ICMs were detected in ten of 24 and six of 15 blastocysts injected with *Jarid2*-null ESCs in two independent experiments. White dotted lines indicate the Nanog-high compartment corresponding to the developing epiblast. Scale bar, 10 μm.\
(F) Confocal image of E4.5 blastocyst after injection of GFP-labeled E8 cells (green) (as in E) showing induction of Gata6 (red) in adjacent wild-type cells. Scale bar, 10 μm.\
See also [Figure S5](#mmc1){ref-type="supplementary-material"}.](gr5){#fig5}

###### 

Multiple ICMs are Induced in E3.5 Mouse Blastocysts Injected with *Jarid2*-Null, Prickle1/Fzd2/Wnt9a-Depleted, or Nanog-Overexpressing ESCs

  ESC                    Number of Blastocysts Injected/Analyzed   Number of Blastocysts with \>1 ICM (%)
  ---------------------- ----------------------------------------- ----------------------------------------
  JM8^+/+^               90                                        0
  E8^--/--^              39                                        16 (41)
  E14                    62                                        0
  Jarid2^CRISPR^\#3      40                                        14 (35)
  PCP^CRISPR^\#5         23                                        11 (48)
  Nanog-OE               43                                        19 (44)
  *Eed*-deficient B1.3   27                                        0

[^1]: Co-first author
